Posts: 168
Threads: 0
Joined: Jul 2017
Reputation:
1
thanks for sharing. ive got a stake in dawnrays. i largely agree with it. in a sense the pharma game has changed in china since the two invoice system and/or central procurement was introduced, so old margins cant be enjoyed any longer. my bet is essentially that the management team with its experience and wide network and alignment of interest can find a way to thrive in the new normal.
a few small comments. i like their relatively clean and straightforward org structure, makes the company ops easier to understand. i attended the agm last year and asked about their wealth management products, which have been increasing in amount lately. no one present could answer the question and the chair rang up some finance person (perhaps the CFO) and put him on speaker in front of the mic to answer in mandarin,basically giving assurance the products were safe stuff. that was a weird scene.
Posts: 98
Threads: 17
Joined: May 2013
Reputation:
4
@karlmarx, agree with your thoughts. This should usually go into the too hard pile. It took us 6 years of reading and understanding before we pulled the trigger on this. Hopefully, we have knew enough to make this a profitable position.
@BRT, glad to know that you attended the AGM last year. Personally, we had encountered a few funny situation with Chinese founders on our own. A few times, we immediately sold out of the company. The biggest risk for Dawnrays have to be fraud and that the wealth management product is non-existent but the insider purchase and the share buyback and repurchase do reassure us quite a bit.